COMMUNIQUÉS West-GlobeNewswire

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
12/10/2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE [...]
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
12/10/2026
– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to [...]
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
12/10/2026
AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after [...]
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
12/10/2026
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative [...]
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
12/10/2026
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term Three patent applications are pending, including two method [...]
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
12/10/2026
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. [...]
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12/10/2026
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for [...]
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
12/10/2026
PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
12/10/2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
12/10/2026
CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. ( [...]
PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
12/10/2026
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
12/10/2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports [...]
Broken Tooth in West Hollywood? Same-Day Extraction and Implant Placement May Be an Option for Qualifying Patients
12/10/2026
A 427-dentist study in the Journal of Dentistry found extraction recommendations rose from under 1% to about 52% as periodontal involvement went from mild to severe. Los Angeles Advanced Dentistry in West Hollywood [...]
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
12/10/2026
Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a [...]
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
12/10/2026
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market [...]
Teva to Host R&D Day on Wednesday, November 11 in New York City
12/10/2026
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s [...]
NexLife Announces October 2026 GLP-1 Price Index on Online Prices of Compounded Tirzepatide and Semaglutide
13/10/2026
WILMINGTON, Del., Oct. 12, 2026 (GLOBE NEWSWIRE) -- NexLife announces a new report, the October 2026 NexLife GLP-1 Price Index, on the monthly prices of compounded tirzepatide and compounded semaglutide at online [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Septembre 2026
12/10/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]

Pages